Leniolisib for Immune Dysregulation in PIDs (clinicaltrials.gov) - Oct 20, 2026 - P2 | N=13 | Completed | Sponsor: Pharming Technologies B.V. | Active, not recruiting ➔ Completed | Trial completion date: Nov 2026 ➔ Jun 2026 | Trial primary completion date: Nov 2026 ➔ Jun 2026
Trial completion • Trial completion date • Trial primary completion date • Immunology • Primary Immunodeficiency • CTLA4 • PTEN • SOCS1
|